Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical data being presented at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 28, 2025 at 8:30 AM ET.